-+ 0.00%
-+ 0.00%
-+ 0.00%

BELITE BIO, - FDA ACCEPTS NDA WITH PRIORITY REVIEW FOR TINLAREBANT; PDUFA TARGET DATE FEB 12, 2027

Reuters·09/08/2026 10:00:00

Please log in to view news